2,644 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,644 shares of the medical equipment provider's stock, valued at approximately $237,000.

Several other institutional investors also recently made changes to their positions in LNTH. Geode Capital Management LLC lifted its holdings in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in Lantheus in the third quarter valued at $25,955,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after acquiring an additional 3,772 shares during the period. Empirical Asset Management LLC bought a new position in shares of Lantheus during the fourth quarter worth about $323,000. Finally, Focus Financial Network Inc. acquired a new stake in shares of Lantheus in the 4th quarter worth about $292,000. 99.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on LNTH shares. B. Riley decreased their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. JMP Securities restated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. Finally, Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Remove Ads

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 in the last three months. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Performance

NASDAQ LNTH traded down $1.39 on Thursday, reaching $97.04. The company's stock had a trading volume of 681,764 shares, compared to its average volume of 930,255. The firm's 50 day moving average is $93.01 and its two-hundred day moving average is $96.47. The stock has a market cap of $6.65 billion, a PE ratio of 16.15 and a beta of 0.38. Lantheus Holdings, Inc. has a twelve month low of $58.16 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.